$3.66
Comments
Loading...
HLS Therapeutics Analyst Ratings and Price Targets | OTC:HLTRF | Benzinga
HLS Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for HLS Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Raymond James
1calculated from analyst ratings
Analyst Ratings for HLS Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/18/2024 | Buy Now | — | Raymond James | Rahul Sarugaser20% | $6.5 → $5 | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for HLS Therapeutics (HLTRF) stock?
The latest price target for HLS Therapeutics (OTCPK:HLTRF) was reported by Raymond James on March 18, 2024. The analyst firm set a price target for $5.00 expecting HLTRF to fall to within 12 months (a possible NaN% downside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for HLS Therapeutics (HLTRF)?
The latest analyst rating for HLS Therapeutics (OTCPK:HLTRF) was provided by Raymond James, and HLS Therapeutics maintained their market perform rating.
When was the last upgrade for HLS Therapeutics (HLTRF)?
There is no last upgrade for HLS Therapeutics
When was the last downgrade for HLS Therapeutics (HLTRF)?
There is no last downgrade for HLS Therapeutics.
When is the next analyst rating going to be posted or updated for HLS Therapeutics (HLTRF)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HLS Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HLS Therapeutics was filed on March 18, 2024 so you should expect the next rating to be made available sometime around March 18, 2025.
Is the Analyst Rating HLS Therapeutics (HLTRF) correct?
While ratings are subjective and will change, the latest HLS Therapeutics (HLTRF) rating was a maintained with a price target of $6.50 to $5.00. The current price HLS Therapeutics (HLTRF) is trading at is $undefined, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
